Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome.
OBJECTIVE: Adverse events (AEs) are health related events, reported by participants in clinical trials. We describe AEs in the PACE trial of treatments for chronic fatigue syndrome (CFS) and baseline characteristics associated with them. METHODS: AEs were recorded on three occasions over one year in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1797064207516041216 |
|---|---|
| author | Dougall, D Johnson, A Goldsmith, K Sharpe, M Angus, B Chalder, T White, P |
| author_facet | Dougall, D Johnson, A Goldsmith, K Sharpe, M Angus, B Chalder, T White, P |
| author_sort | Dougall, D |
| collection | OXFORD |
| description | OBJECTIVE: Adverse events (AEs) are health related events, reported by participants in clinical trials. We describe AEs in the PACE trial of treatments for chronic fatigue syndrome (CFS) and baseline characteristics associated with them. METHODS: AEs were recorded on three occasions over one year in 641 participants. We compared the numbers and nature of AEs between treatment arms of specialist medical care (SMC) alone, or SMC supplemented by adaptive pacing therapy (APT), cognitive behaviour therapy (CBT) or graded exercise therapy (GET). We examined associations with baseline measures by binary logistic regression analyses, and compared the proportions of participants who deteriorated by clinically important amounts. RESULTS: Serious adverse events and reactions were infrequent. Non-serious adverse events were common; the median (quartiles) number was 4 (2, 8) per participant, with no significant differences between treatments (P=.47). A greater number of NSAEs were associated with recruitment centre, and baseline physical symptom count, body mass index, and depressive disorder. Physical function deteriorated in 39 (25%) participants after APT, 15 (9%) after CBT, 18 (11%) after GET, and 28 (18%) after SMC (P<.001), with no significant differences in worsening fatigue. CONCLUSIONS: The numbers of adverse events did not differ significantly between trial treatments, but physical deterioration occurred most often after APT. The reporting of non-serious adverse events may reflect the nature of the illness rather than the effect of treatments. Differences between centres suggest that both standardisation of ascertainment methods and training are important when collecting adverse event data. |
| first_indexed | 2024-03-06T21:10:57Z |
| format | Journal article |
| id | oxford-uuid:3e221b62-7221-43ca-9496-bb2c755e24c7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:10:57Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:3e221b62-7221-43ca-9496-bb2c755e24c72022-03-26T14:23:45ZAdverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3e221b62-7221-43ca-9496-bb2c755e24c7EnglishSymplectic Elements at Oxford2014Dougall, DJohnson, AGoldsmith, KSharpe, MAngus, BChalder, TWhite, POBJECTIVE: Adverse events (AEs) are health related events, reported by participants in clinical trials. We describe AEs in the PACE trial of treatments for chronic fatigue syndrome (CFS) and baseline characteristics associated with them. METHODS: AEs were recorded on three occasions over one year in 641 participants. We compared the numbers and nature of AEs between treatment arms of specialist medical care (SMC) alone, or SMC supplemented by adaptive pacing therapy (APT), cognitive behaviour therapy (CBT) or graded exercise therapy (GET). We examined associations with baseline measures by binary logistic regression analyses, and compared the proportions of participants who deteriorated by clinically important amounts. RESULTS: Serious adverse events and reactions were infrequent. Non-serious adverse events were common; the median (quartiles) number was 4 (2, 8) per participant, with no significant differences between treatments (P=.47). A greater number of NSAEs were associated with recruitment centre, and baseline physical symptom count, body mass index, and depressive disorder. Physical function deteriorated in 39 (25%) participants after APT, 15 (9%) after CBT, 18 (11%) after GET, and 28 (18%) after SMC (P<.001), with no significant differences in worsening fatigue. CONCLUSIONS: The numbers of adverse events did not differ significantly between trial treatments, but physical deterioration occurred most often after APT. The reporting of non-serious adverse events may reflect the nature of the illness rather than the effect of treatments. Differences between centres suggest that both standardisation of ascertainment methods and training are important when collecting adverse event data. |
| spellingShingle | Dougall, D Johnson, A Goldsmith, K Sharpe, M Angus, B Chalder, T White, P Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. |
| title | Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. |
| title_full | Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. |
| title_fullStr | Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. |
| title_full_unstemmed | Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. |
| title_short | Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. |
| title_sort | adverse events and deterioration reported by participants in the pace trial of therapies for chronic fatigue syndrome |
| work_keys_str_mv | AT dougalld adverseeventsanddeteriorationreportedbyparticipantsinthepacetrialoftherapiesforchronicfatiguesyndrome AT johnsona adverseeventsanddeteriorationreportedbyparticipantsinthepacetrialoftherapiesforchronicfatiguesyndrome AT goldsmithk adverseeventsanddeteriorationreportedbyparticipantsinthepacetrialoftherapiesforchronicfatiguesyndrome AT sharpem adverseeventsanddeteriorationreportedbyparticipantsinthepacetrialoftherapiesforchronicfatiguesyndrome AT angusb adverseeventsanddeteriorationreportedbyparticipantsinthepacetrialoftherapiesforchronicfatiguesyndrome AT chaldert adverseeventsanddeteriorationreportedbyparticipantsinthepacetrialoftherapiesforchronicfatiguesyndrome AT whitep adverseeventsanddeteriorationreportedbyparticipantsinthepacetrialoftherapiesforchronicfatiguesyndrome |